STM2457, a potent, selective, and orally active METTL3 catalytic inhibitor, has shown promising anti-tumor effects in various cancers, including acute myeloid leukemia (AML), intrahepatic cholangiocarcinoma (ICC), and neuroblastoma [41–43]. Here, METTL3 is linked to neoplasm.